Post-earnings recap
Reported
Wed, Aug 5, 2026
EPS actual
$-1.97
EPS est.
$-1.47
EPS surprise
-34.01%
1-day move
+2.25%
Vaxcyte reported a larger-than-expected loss per share, which typically raises concerns among investors. However, the stock still rose by 2.25%, possibly indicating that investors were looking for a buying opportunity or had lower expectations. The lack of revenue data and management commentary leaves uncertainty about the company's performance and future direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.97 | N/A | -34.01% |
| Revenue | — | N/A | — |
No transcript is on record, and the analysis is based solely on numerical results.
Vaxcyte, Inc. is a biotechnology company focused on developing innovative vaccines to address serious infectious diseases. Operating in the health care sector, Vaxcyte's work is particularly relevant as global health challenges continue to evolve, highlighting the need for effective vaccination solutions.
Last quarter
In Q1-2026, Vaxcyte reported an EPS of -$2.30, missing estimates by nearly 24%. Despite the miss, the stock rose by 2.62% the following day, indicating some investor optimism.
Management promises and guidance
EPS beat streak
0Q
EPS beat rate
13%
Avg EPS surprise
-46.50%
Avg 1-day reaction
+0.36%
Overall, expectations are mixed as Vaxcyte continues to navigate challenges in vaccine development and market competition. Investors are keenly watching for any signs of progress.
Bull case
If Vaxcyte can demonstrate significant advancements in its vaccine pipeline, it could lead to increased investor confidence and a strong stock performance.
Bear case
Conversely, if the company fails to meet expectations or provide positive updates on its vaccine candidates, it could lead to a negative reaction from the market.
The print will turn on these.
Q1
What is the current status of Vaxcyte's vaccine candidates and any upcoming milestones?
Progress on vaccine candidates is crucial for future revenue and investor confidence.
Q2
How does Vaxcyte plan to address the recent earnings misses and improve profitability?
Management's strategy for overcoming past performance issues will be key to shaping market expectations.
—
Est. EPS
—
Est. Rev
—
Impl. Move
±12.7%
Why consensus could be wrong
The Street may underestimate the potential for Vaxcyte's vaccine candidates to gain traction in a competitive market, especially if they can demonstrate unique advantages.
Supporting evidence
Options are pricing a 22.18% move, suggesting the market anticipates significant developments.
The company has a strong pipeline that could surprise investors if progress is made.
Past earnings reactions indicate that even missed expectations can lead to positive stock movements if accompanied by strong narratives.
Key risk
If Vaxcyte announces significant advancements in its vaccine candidates, it could shift market sentiment dramatically.
Pre-commit to what would confirm each case.
The core debate centers around Vaxcyte's ability to advance its vaccine pipeline amidst competitive pressures and operational challenges.
Bull confirmed if
Demonstrating progress in vaccine development with at least one candidate entering late-stage trials.
Bear confirmed if
Failure to provide clear timelines or updates on vaccine candidates, indicating potential delays.
What the market is pricing for the move.
Implied Move
±22.18%
Historical Avg
±2.0%
The options market is pricing in a significant potential move, indicating heightened uncertainty ahead of the earnings report.
Options are pricing ±22.2% while PCVX has averaged ±2.0% over the last 8 prints — setup is pricing rich.
ATM IV
0.5%
30d HV
49.6%
Cross-company pattern from 30 similar setups.
Prior-quarter miss + options pricing rich in Health Care
Fade rate: 13 of 29 (45%)
This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 3.6%, with a raw directional average of -1.3% (modestly negative historical bias).
Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.
Bought
$0.00
0 sh
0 insiders
Sold
$3.3M
39,250 sh
2 insiders
Net
$3.3M
Net selling
Most Active Insiders· 4 open-market trades
$1.7M
Net selling
Smart-money positioning from the most recent 13F filings.
Institutional
113.47%
of float
Insider
0.50%
of float
Holders
458
institutions
Top Holders· as of Jun 2026
FMR, LLC
20,852,907 sh · $1.4B
14.01%
26.4%
Likely market behavior by outcome. Not investment advice.
Beat & raise
If Vaxcyte beats expectations, history suggests the stock could see a modest uptick, confirming a positive trajectory in vaccine development.
In line / cautious
An in-line report may lead to a muted reaction, as investors await more concrete guidance on future developments.
Miss
A miss could result in a decline, with history suggesting an average drop of around 0.06% following earnings misses.
House and Senate STOCK Act disclosures over the trailing 6 months.
Trades
3
3 buys·0 sells
Members
1
House only
Est. Notional
$3,003.00–$45,000.00
disclosed dollar ranges
Most Active Members
3 trades
The lines on the call that would change the story.
$1.6M
Net selling
Recent Transactions
Oct 5, 2026 · @ $86.74
19,000 sh
$1.6M
Oct 5, 2026 · @ $86.74
18,000 sh
$1.6M
Oct 1, 2026 · @ $56.65
2,155 sh
$122,089.37
Oct 1, 2026 · @ $57.09
95 sh
$5,423.93
Open-market trades only (Form 4 codes P/S). Awards, exercises, and tax-withholding excluded as routine compensation noise.
Jupiter Topco LLC
17,965,847 sh · $1.2B
12.07%
100.0%
T. Rowe Price Investment Management, Inc.
12,207,450 sh · $817.4M
8.20%
0.7%
Blackrock Inc.
12,068,129 sh · $808.1M
8.11%
10.0%
RA Capital Management, L.P.
11,474,599 sh · $768.3M
7.71%
Flat
13F filings updated quarterly. Position deltas show change in shares vs. the prior quarter.
Net buying
Recent Transactions
Traded Jul 16, 2026 · disclosed Sep 4, 2026
$1,001.00–$15,000.00
Traded May 13, 2026 · disclosed Jun 8, 2026
$1,001.00–$15,000.00
Traded May 12, 2026 · disclosed Jun 8, 2026
$1,001.00–$15,000.00
Filed 30–45+ days after the trade. Treat as positional context, not a leading indicator. Amounts are SEC-mandated dollar ranges, not exact values.